Shark Tank Original Member Kevin Harrington Joins Forces with UVLrx Therapeutics, Inc.
OLDSMAR, Fla.--(BUSINESS WIRE)-- UVLrx Therapeutics, Inc. announces its partnership with Kevin Harrington, investor, inventor, and one of the original "sharks" on the hit ABC television series, “Shark Tank”. Harrington will oversee the marketing and growth of the company’s light therapy devices, which deliver multiple visible light wavelengths intravenously to treat a variety of conditions through the bloodstream.
“I’ve been introduced to thousands of products from around the world and I’ve never had the opportunity to represent a product, let alone a medical device, that could change medical history as we know it,” says Harrington. “I’m thrilled to be on this team and I look forward to the positive impact UVLrx Therapeutics, will have on global healthcare.”
Over the past 30 years, Harrington’s products and businesses have exceeded $5 Billion USD in sales across 100 countries. He was also the pioneer of As Seen On TV.
“Kevin has a reputation for identifying viable, high-impact businesses and growing them into industry leaders,” says UVLrx Therapeutics founder Michael Harter. “His contributions as an advisor and investor will allow us to expand the distribution of our light therapy treatment system around the world, which means we’ll reach more people and animals in need.”
UVLrx treatment systems emit three wavelengths of light in a unique parallel combination. RED light (630nm), UVA light (365nm), and GREEN light (530nm) are seamlessly integrated into an IV catheter illuminating the passing blood supply. Using the company’s patented Dry Light Adapter™ integration with an IV, the device treats blood intravenously.
Literature has shown these three wavelengths may have potential benefits with:
- Reduction of inflammation
- Improved wound healing
- Improved ATP synthesis
- Immune system modulation
About UVLrx Therapeutics, Inc.
Based in Oldsmar, Florida, UVLrx Therapeutics is dedicated to evidence-based medicine in the field of light therapy and offers the first known intravenous, concurrent delivery of Ultraviolet-A (UVA), RED and GREEN light wavelengths. In addition to two Nobel Prizes and NASA-backed research, hundreds of international clinical trials have verified the health benefits of UV and other wavelengths of light utilized in the UVLrx™ Treatment System.
For more information, please email firstname.lastname@example.org or call 844-885-7979.
UVLrx Therapeutics, Inc.
Michael Harter, CEO / Founder